We have investigated the role of biochemical markers in breast and lung cancer but have found that currently available tests have little role in management. In breast cancer, for example, we have found that the most sensitive method for routine screening for metastases is by using chest x-ray and clinical examination, liver function tests, and carcinoembryonic antigen measurements. We are now examining other methods for detecting metastases using immunocytochemistry in cytological preparations of bone marrow and attempting to raise monoclonal antibodies to breast cancer cells. In lung cancer, the major effort has been directed towards characterisation of large-molecular-weight ectopic hormones, particularly calcitonin.
To some extent the needs of the clinician are different, depending on whether or not he is treating breast or lung cancer. The clear need in patients presenting with breast cancer is for a marker to distinguish patients with metastatic disease from those who do not have metastases or who will not develop symptomatic metastases. In small-cell lung cancer, the need is for a marker to monitor systemic treatment and Breast cancer also to predict which patients are likely to respond to treatment, since in this disease metastases are MARKERS IN PLASMA AND URINE present in the vast majority of patients and will cause We now doubt the value of the majority of available death in all but a minority. Squamous-cell lung plasma and urine markers in this disease. Some of cancer is still treated by surgery, and the require-these that we have investi gated are listed in Table 1 ments of a biochemical test are similar to those of along with the number and incidence of abnormalities the clinician dealing with breast cancer.
in early and late breast cancer, respectively. It is Common to all types of breast and lung cancer, clear that most of the markers are non-specific, and however, is the need for improved means of treat-few if any are abnormal in early breast cancer. The ment since current therapy consists of only partially patients with early breast cancer and abnormal tests and temporarily effective agents. There seems little have a similar prognosis to those with normal doubt, however, that systemic treatment given markers.' earlier in the course of the disease in either breast or Table 1 shows also that some of the tests are more lung cancer will improve the length of survival of frequently abnormal than others in patients with patients so treated, provided adequate markers are advanced disease, and there are nine tests that are established to determine the efficacy of therapy. A abnormal in more than 50% of patients. We therefore prime example of this at the present time is the assessed these markers in 23 patients who presented measurement of steroid hormone receptors in the with no evidence of metastases and received treatcytosol of breast tumours. The presence of these ment for their primary breast cancer. They were all receptors will predict response to systemic endocrine followed up at three-monthly intervals, and on each therapy to a fair extent, and this indicates that this occasion a sample of blood was taken for marker test should now be used to select patients for estimation. All patients developed metastatic disadjuvant hormone treatment.
ease. The results shown in Figs 1 and 2 express the Aside from simple directives for therapeutic results as percentages of patients who had an strategy, however, we have to consider a longer-abnormal marker at each time interval before 263 (y-GT), and alkaline phosphatase seemed to be the most suitable markers. Several of the others were abnormal at intervals before the development of metastases, but, on the whole, these had no benefit when added to y-GT, alkaline phosphatase, or CEA in a multiparametric appraisal. This is illustrated in Fig. 3 , and it can be seen that a similar number of patients would have been detected at each time interval had only these three markers been used. We are currently investigating the value of these markers prospectively in screening for metastases at primary presentation. Abnormalities are seen in only very few patients, as is shown in Table 2 . Here the markers are compared with clinical examination, chest x-ray, and bone scan. In this group of patients presenting with primary breast cancer 13/240 (6·1 %) were shown to have metastatic disease, and of these patients all but one would have been detected by clinical examination, chest x-ray, alkaline phosphatase estimation, and questioning for bone pain. A history of bone pain should be elucidated by a full radiological skeletal survey since bone scan can often be misleading. Therefore at the present time we screen patients with estimations of y-GT and alkaline phosphatase, and chest x-ray is also carried out. At present we also obtain a base-line bone scan in order to compare subsequent scans in the event of bone pain developing later. A base-line skeletal survey is not considered necessary in the absence of bone pain.
IMMUNOCYTOCHEMICAL MARKERS IN

PLEURAL FLUID AND BONE MARROW
Methods have now been developed for localising various markers within cells using immunocytochemistry. In breast cancer there are currently two antigens that are identifiable as being present in cancer cells. One is carcinoembryonic antigen (CEA) , which has been mentioned above and is present on the surface of breast cancer cells. Antibodies have been raised to CEA, and staining for CEA in sections can sometimes help to detect cells in body fluids. The second candidate is epithelial membrane antigen (EMA). This is a glycoprotein that is recognised by antibodies raised in animals after immunisation with defatted milk", EMA is present in the majority of epithelial cells, and antiserum to EMA also stains all malignant breast tissue so far examined but does not generally stain non-epithelial cells. Therefore the distribution of this material in body fluids and bone marrow has been examined since it could help to distinguish cancer from non-cancer tissue.
Use of antisera to epithelial membrane antigen in the cytodiagnosis of malignancy in serous effusions 3 In this study 121 effusions from pleura and peritoneal cavity were obtained from 66 patients with cancer and from 30 patients with various non-malignant diseases. Of the 121 samples 57 (47%) were found to contain malignant cells; 49 (40 %) effusions were found to contain no evidence of cancer cells but the remaining 15 (12 %) were deemed as being suspicious. The pattern of EMA staining is shown in Table 3 . Although weak staining was seen in some benign effusions a strong reaction was not observed, and there is a clear association between strong EMA staining and malignancy and between the absence of EMA expressions and non-malignancy. Utilising these associations, eight out of the 15 cytologically suspicious effusions could be classified as benign or malignant according to their immunocytochemical staining reaction. Further studies using the antiserum are underway to determine the role of immunocytochemical staining in clinical management.
Application of immunocytochemistry to bone marrow examination
We have examined the use of this stain in looking for cells in bone marrow samples. Although only a fraction of patients (lout of 254 in our series) are found to have malignant cells in the bone marrow at presentation with breast cancer, it is possible that we could increase the detection rate by examining larger quantities of marrow and also by using immunocytochemical techniques. At first we simply looked at staining in histological sections of bone marrow aspirates! but we have subsequently examined staining of cytological smears. Seventy-four marrow aspirates were obtained from 71 patients with breast cancer. Of these patients 20 had primary breast cancer with no evidence of metastases, 10 were being followed up and have no metastases, and 44 patients had metastatic breast cancer, including 24 with bone metastases. All aspirates were obtained as a single aspirate from the posterior iliac crest and were stained with anti-EMA. A comparative result of the anti-EMA, Giemsa, and Luke's preparation in detecting marrow infiltration is shown in Table 4 , where it can be seen that a larger number of malignant cells are detected with epithelial membrane antigen.s When we examined the rate of detection in various groups of patients with breast cancer ( Table 5) we found that some patients with no evidence of metastases had EMA-positive cells in the bone marrow.
This is only a preliminary study but it does suggest that this stain may have an application, particularly if larger numbers of bone marrow samples are obtained and stained after a cell separation procedure. We have already carried out such a procedure using a rosetting technique and cells are then separated on a gradient. This enables a far smaller number of slides to be examined using the antiserum, and we anticipate that it will be of clinical value in detecting patients with early metastatic disease,"
FUTURE DIRECTIONS
It is the work of Milstein that has permitted us to examine cell surfaces in greater detail. 7 Thus, we now have hybrids of lymphocytes from sensitised mouse spleen cells and myeloma cells that produce monoclonal antibody to breast cancer cell surfaces and which, hopefully, we can substitute for polyclonal conventional antisera. Whether cell separation can be achieved using these reagents is not yet known, but the results of studies using monoclonal antibodies to T cells suggest that there may be a future in using these antisera to separate cells from heterogeneous populations.
A further approach that may be of value is to examine the cell surfaces of cells constituting the metastases rather than the primary tumour since there is evidence that they may differ in experimental systems." To test this theory, we have recently obtained a cell line derived from a rat mammary tumour." Clones of this cell line have now been obtained, and hopefully we will find that some have specificity for a particular organ. Such specificity could correlate with a surface change that is responsible, and clearly antisera to this component could prove useful in identifying the cells responsible for metastases in any primary tumour. Such a study would then be carried out in human breast cancer. Table 6 lists the incidence of abnormalities for various markers in this desease.'? The situation appears to be fairly similar to the one that we have observed in breast cancer in that it is not until overt metastatic disease has developed that markers rise to any great extent in lung cancer of either the small-cell or the squamous-cell type. A recent review by Sappino et alP at our Institute has examined the value of CEA, calcitonin, and HCG estimations in predicting response to chemotherapy. In this study no relationship between extent of disease and degree of elevation of calcitonin or HCG was seen. As previously reported'", CEA concentrations were related to extent of disease. Concerning the correlation with outcome of chemotherapy there was no relationship between CEA or HCG and response to treatment but those with high plasma calcitonin concentrations appeared to have poorer response rates. These are preliminary data, and further studies are needed to confirm these observations.
ABNORMAL FORMS OF HUMORAL MARKERS
Most of the studies at our Institute have concentrated on hormone production by lung carcinomas in the hope that purification and characterisation of such hormones may provide us with information that could permit suitable means of ectopic hormone detection. The majority of the work has been directed towards ectopic calcitonin purification.
Calcitonin was first found in a human lung carcinoma in 1973,13 and this was followed by our observation'< that the plasma of many patients with lung carcinoma contained a higher calcitonin content than that of controls. Subsequently, several groups found that thyroid-derived calcitonin was heterogeneous's 16 and we then showed that this was true for a lung carcinoma secreting calcitonin in vitroF' Since this time we have examined this material in greater depth.IS 19 Gel-filtration chromatography of medium cocultivated with the lung carcinoma (the 'BEN' cell line) showed that it possessed a principal peak of 28 000 mol. wt. and a broad area of immunoreactive calcitonin mol. wt. 10 000-13 000. There was no material co-eluting with calcitonin monomer at 3500 mol. wt.
High-pressure liquid chromatography showed that the high-molecular-weight material (originally 40 (00) was unstable and degraded through 28 000 to a 10 000 mol. wt. material that appeared relatively stable, and this was the major material provided by 267 immunoprecipitation. Peptide mapping of this compound was carried out after internal labelling and trypsin digestion. This demonstrated that the large-molecular-weight component shared several peaks in common with the peptide maps of human monomeric calcitonin treated in a similar way. Further studies are necessary now to purify the portion of this material that is not common to native monomeric calcitonin.P
The 'BEN' cell line also possesses calcitonin receptors.t" and it was therefore of interest to establish whether any of the forms of calcitonin that it produced was capable of binding to these. Although these receptors may not be identical with 'normal' calcitonin-binding sites on kidney or bone cells, they show similar responses in terms of adenyl cyclase stimulation.
Fractions obtained from chromatography were pooled and freeze-dried, but neither peak of BENderived calcitonin showed significant binding ability, nor did high-molecular-weight peaks obtained from medullary thyroid carcinoma." These results indicate that it is unlikely that the materials produced by these cells have significant biological activity.
Conclusions
It is clear that clinicians would benefit immensely from a simple method of monitoring patients. Currently, however, no such marker has been shown to be suitable. Several laboratories have suggested individual markers, but none has been found to be clinically valuable after adequate tests. This indicates that a reappraisal of our strategy is necessary and a new approach towards examining cancer markers is needed.
In the meantime, however, we recommend that biochemical and other staging techniques used in cancer patients are kept to a minimum. Thus the majority of patients with breast cancer can be monitored using liver function tests and chest x-ray until they relapse when skeletal surveys become important as aids to assessment of treatment and directing radiotherapy. In lung cancer the same applies although should a humoral syndrome be apparent then obviously sequential hormone estimation might be useful in monitoring the disease.
